TAKE A HIT OR LET IT SIT?
On the weekly chart,
TOKE has sold out of the alternative semi-correction which has lead the price action south to the 5th wave of the semi-cycle pivot. MACD divergence seems to be peaking through the weekly signals, applying towards the 4th-5th alternative correction timeframe and assume this divergence will continue displaying throughout the primary 5th wave.
Since the ticker tag is under $10.19, I believe the semi-cycle correction is done and over with and will be on the south side of town until the 5th of the primary cycle target, which I think will start to gain traction around $8.35 -- $7.63 (wave 1 polar) possible floor for cycle correction.
*Bonus thought: This seems to be selling without Aug. and leading into Sept. With Cambria Cannabis ETF holding a lot of Canadian stocks, one might think this continues to sell when the US cannabis stocks are ready to make a correction move in Aug.
On the weekly chart,
TOKE has sold out of the alternative semi-correction which has lead the price action south to the 5th wave of the semi-cycle pivot. MACD divergence seems to be peaking through the weekly signals, applying towards the 4th-5th alternative correction timeframe and assume this divergence will continue displaying throughout the primary 5th wave.Since the ticker tag is under $10.19, I believe the semi-cycle correction is done and over with and will be on the south side of town until the 5th of the primary cycle target, which I think will start to gain traction around $8.35 -- $7.63 (wave 1 polar) possible floor for cycle correction.
*Bonus thought: This seems to be selling without Aug. and leading into Sept. With Cambria Cannabis ETF holding a lot of Canadian stocks, one might think this continues to sell when the US cannabis stocks are ready to make a correction move in Aug.
Penerbitan berkaitan
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penerbitan berkaitan
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.